

Asia Pacific Vaccine Market Report and Forecast 2024-2032

Market Report | 2023-12-08 | 188 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Asia Pacific Vaccine Market Report and Forecast 2024-2032

Market Outlook

According to the report by Expert Market Research (EMR), the Asia Pacific vaccine market is projected to grow at a CAGR of 7.8% between 2024 and 2032. Aided by the escalating need for immunisation against prevalent infectious diseases and the region's commitment to public health, the market is expected to grow significantly by 2032.

Vaccines, critical in promoting immunity against a plethora of infectious diseases, have become a cornerstone in the public health agenda of many Asia Pacific nations. These biological preparations, which utilise a disease-causing microorganism or its toxins, prime the immune system to combat infections. Their significance spans beyond individual health, ensuring herd immunity and curbing epidemics.

As per the Asia Pacific vaccine market analysis, the Asia Pacific, characterised by its diverse demographics and vast population, has witnessed a surge in vaccine demand. Countries like India and China have vast immunization programs, catering to their billion-plus populations, while others like Japan and South Korea have showcased advanced research and development in novel vaccine formulations.

The burgeoning population, especially the paediatric and geriatric cohorts, has amplified the need for routine immunisations and contribute to the Asia Pacific vaccine market growth. Coupled with this is the increasing cognisance about the significance of vaccines, driven by governmental campaigns and international collaborations.

Moreover, the recent COVID-19 pandemic accentuated the urgency of vaccine research, development, and distribution. The Asia Pacific became a hub of vaccine manufacturing, with countries like India earning the moniker "Pharmacy of the World" for its vast vaccine exports which propelled the Asia Pacific vaccine market demand.

The market's vigour is further sustained by the region's drive to combat diseases like influenza, tuberculosis, and hepatitis.

Investments in vaccine research have been notable, with biotechnology parks and innovation hubs sprouting across countries.

Additionally, international collaborations, such as the partnership between GAVI, the Vaccine Alliance, and various Asian nations, have bolstered vaccine accessibility and affordability and are major contributors to the Asia Pacific vaccine market size.

Technological innovations, such as drone deliveries for vaccines in remote areas, and digital tracking systems, are revolutionising vaccine distribution. Moreover, public-private partnerships are channelling funds, technology, and expertise to bolster the region's

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

vaccine arsenal.

Market Segmentation □

The market can be divided based on technology, indication, end use, and country.

Market Breakup by Technology

- Recombinant and Conjugate Vaccine
- Inactivated Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Others

Market Breakup by Indication

- Pneumococcal Disease
- Influenza
- Human Papilloma Virus
- Meningococcal Disease
- Rotavirus
- Varicella, Measles, Mumps, and Rubella
- Diphtheria, Pertussis, and Tetanus (DPT)
- Polio
- Hepatitis
- JE (Japanese Encephalitis) Vaccine
- Others

Market Breakup by End Use

- Paediatric Vaccine
- Adult Vaccine
- Travellers Vaccine

Market Breakup by Country

- China
- India
- Japan
- ASEAN
- Australia
- Others

Competitive Landscape

The EMR report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the Asia Pacific vaccine market. Some of the major players explored in the report by Expert Market Research are as follows:

- CSL Limited
- Bharat Biotech
- GlaxoSmithKline plc
- Novartis AG
- Pfizer Inc.
- AstraZeneca plc.
- Others

About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Our high-quality, data-driven analysis provides the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.

Don't miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organisation's future success by acquiring one of our Expert Market Research reports today.

*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
- 2 Report Coverage - Key Segmentation and Scope
- 3 Report Description
 - 3.1 Market Definition and Outlook
 - 3.2 Properties and Applications
 - 3.3 Market Analysis
 - 3.4 Key Players
- 4 Key Assumptions
- 5 Executive Summary
 - 5.1 Overview
 - 5.2 Key Drivers
 - 5.3 Key Developments
 - 5.4 Competitive Structure
 - 5.5 Key Industrial Trends
- 6 Snapshot
 - 6.1 Asia Pacific
- 7 Opportunities and Challenges in the Market
- 8 Asia Pacific Vaccine Market Overview
 - 8.1 Key Industry Highlights
 - 8.2 Asia Pacific Vaccine Historical Market (2018-2023)
 - 8.3 Asia Pacific Vaccine Market Forecast (2024-2032)
 - 8.4 Asia Pacific Vaccine Market by Technology
 - 8.4.1 Recombinant and Conjugate Vaccine
 - 8.4.1.1 Historical Trend (2018-2023)
 - 8.4.1.2 Forecast Trend (2024-2032)
 - 8.4.2 Inactivated Vaccines
 - 8.4.2.1 Historical Trend (2018-2023)
 - 8.4.2.2 Forecast Trend (2024-2032)
 - 8.4.3 Live Attenuated Vaccines
 - 8.4.3.1 Historical Trend (2018-2023)
 - 8.4.3.2 Forecast Trend (2024-2032)
 - 8.4.4 Toxoid Vaccines
 - 8.4.4.1 Historical Trend (2018-2023)
 - 8.4.4.2 Forecast Trend (2024-2032)
 - 8.4.5 Others
 - 8.5 Asia Pacific Vaccine Market by Indication
 - 8.5.1 Pneumococcal Disease

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5.1.1 Historical Trend (2018-2023)
- 8.5.1.2 Forecast Trend (2024-2032)
- 8.5.2 Influenza
 - 8.5.2.1 Historical Trend (2018-2023)
 - 8.5.2.2 Forecast Trend (2024-2032)
- 8.5.3 Human Papilloma Virus
 - 8.5.3.1 Historical Trend (2018-2023)
 - 8.5.3.2 Forecast Trend (2024-2032)
- 8.5.4 Meningococcal Disease
 - 8.5.4.1 Historical Trend (2018-2023)
 - 8.5.4.2 Forecast Trend (2024-2032)
- 8.5.5 Rotavirus
 - 8.5.5.1 Historical Trend (2018-2023)
 - 8.5.5.2 Forecast Trend (2024-2032)
- 8.5.6 Varicella, Measles, Mumps, and Rubella
 - 8.5.6.1 Historical Trend (2018-2023)
 - 8.5.6.2 Forecast Trend (2024-2032)
- 8.5.7 Diphtheria, Pertussis, and Tetanus (DPT)
 - 8.5.7.1 Historical Trend (2018-2023)
 - 8.5.7.2 Forecast Trend (2024-2032)
- 8.5.8 Polio
 - 8.5.8.1 Historical Trend (2018-2023)
 - 8.5.8.2 Forecast Trend (2024-2032)
- 8.5.9 Hepatitis
 - 8.5.9.1 Historical Trend (2018-2023)
 - 8.5.9.2 Forecast Trend (2024-2032)
- 8.5.10 JE (Japanese Encephalitis) Vaccine
 - 8.5.10.1 Historical Trend (2018-2023)
 - 8.5.10.2 Forecast Trend (2024-2032)
- 8.5.11 Others
- 8.6 Asia Pacific Vaccine Market by End Use
 - 8.6.1 Paediatric Vaccine
 - 8.6.1.1 Historical Trend (2018-2023)
 - 8.6.1.2 Forecast Trend (2024-2032)
 - 8.6.2 Adult Vaccine
 - 8.6.2.1 Historical Trend (2018-2023)
 - 8.6.2.2 Forecast Trend (2024-2032)
 - 8.6.3 Travellers Vaccine
 - 8.6.3.1 Historical Trend (2018-2023)
 - 8.6.3.2 Forecast Trend (2024-2032)
- 8.7 Asia Pacific Vaccine Market by Country
 - 8.7.1 China
 - 8.7.2 India
 - 8.7.3 Japan
 - 8.7.4 ASEAN
 - 8.7.5 Australia
 - 8.7.6 Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9 Regional Analysis
 - 9.1 China
 - 9.1.1 Historical Trend (2018-2023)
 - 9.1.2 Forecast Trend (2024-2032)
 - 9.2 India
 - 9.2.1 Historical Trend (2018-2023)
 - 9.2.2 Forecast Trend (2024-2032)
 - 9.3 Japan
 - 9.3.1 Historical Trend (2018-2023)
 - 9.3.2 Forecast Trend (2024-2032)
 - 9.4 ASEAN
 - 9.4.1 Historical Trend (2018-2023)
 - 9.4.2 Forecast Trend (2024-2032)
 - 9.5 Australia
 - 9.5.1 Historical Trend (2018-2023)
 - 9.5.2 Forecast Trend (2024-2032)
- 10 Market Dynamics
 - 10.1 SWOT Analysis
 - 10.1.1 Strengths
 - 10.1.2 Weaknesses
 - 10.1.3 Opportunities
 - 10.1.4 Threats
 - 10.2 Porter's Five Forces Analysis
 - 10.2.1 Supplier's Power
 - 10.2.2 Buyer's Power
 - 10.2.3 Threat of New Entrants
 - 10.2.4 Degree of Rivalry
 - 10.2.5 Threat of Substitutes
 - 10.3 Key Indicators for Demand
 - 10.4 Key Indicators for Price
- 11 Value Chain Analysis
- 12 Competitive Landscape
 - 12.1 Market Structure
 - 12.2 Company Profiles
 - 12.2.1 CSL Limited
 - 12.2.1.1 Company Overview
 - 12.2.1.2 Product Portfolio
 - 12.2.1.3 Demographic Reach and Achievements
 - 12.2.1.4 Certifications
 - 12.2.2 Bharat Biotech
 - 12.2.2.1 Company Overview
 - 12.2.2.2 Product Portfolio
 - 12.2.2.3 Demographic Reach and Achievements
 - 12.2.2.4 Certifications
 - 12.2.3 GlaxoSmithKline plc
 - 12.2.3.1 Company Overview
 - 12.2.3.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.3.3 Demographic Reach and Achievements
- 12.2.3.4 Certifications
- 12.2.4 Novartis AG
 - 12.2.4.1 Company Overview
 - 12.2.4.2 Product Portfolio
 - 12.2.4.3 Demographic Reach and Achievements
 - 12.2.4.4 Certifications
- 12.2.5 Pfizer Inc.
 - 12.2.5.1 Company Overview
 - 12.2.5.2 Product Portfolio
 - 12.2.5.3 Demographic Reach and Achievements
 - 12.2.5.4 Certifications
- 12.2.6 AstraZeneca plc.
 - 12.2.6.1 Company Overview
 - 12.2.6.2 Product Portfolio
 - 12.2.6.3 Demographic Reach and Achievements
 - 12.2.6.4 Certifications
- 12.2.7 Others

13 Key Trends and Developments in the Market

List of Key Figures and Tables

1. Asia Pacific Vaccine Market: Key Industry Highlights, 2018 and 2032
2. Asia Pacific Vaccine Historical Market: Breakup by Technology (USD Billion), 2018-2023
3. Asia Pacific Vaccine Market Forecast: Breakup by Technology (USD Billion), 2024-2032
4. Asia Pacific Vaccine Historical Market: Breakup by Indication (USD Billion), 2018-2023
5. Asia Pacific Vaccine Market Forecast: Breakup by Indication (USD Billion), 2024-2032
6. Asia Pacific Vaccine Historical Market: Breakup by End Use (USD Billion), 2018-2023
7. Asia Pacific Vaccine Market Forecast: Breakup by End Use (USD Billion), 2024-2032
8. Asia Pacific Vaccine Historical Market: Breakup by Country (USD Billion), 2018-2023
9. Asia Pacific Vaccine Market Forecast: Breakup by Country (USD Billion), 2024-2032
10. Asia Pacific Vaccine Market Structure

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Asia Pacific Vaccine Market Report and Forecast 2024-2032

Market Report | 2023-12-08 | 188 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com